Precision antibiotics based on protein bacteriocins

GLOX Therapeutics Ltd. is at the forefront of developing precision antibiotics aimed at combating antimicrobial resistance (AMR) through the use of engineered protein bacteriocins. These bacteriocins are derived from Gram-negative bacteria and are designed to specifically target drug-resistant pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae. The company leverages over 20 years of research to create potent, species-specific antibiotics that minimize harm to the host microbiome, distinguishing them from conventional antibiotics. The Glox Discovery Platform is adaptable and can be tailored to address various Gram-negative pathogens, with an initial focus on treating conditions like ventilator-associated pneumonia through intravenous delivery of bacteriocin constructs.

The Glox Development Program is dedicated to addressing the urgent need for new antibiotics against pathogens listed on the WHO's critical list of drug-resistant bacteria. The company’s research aims to develop a pipeline of engineered bacteriocins that can effectively treat serious infections associated with high levels of AMR and mortality. By targeting specific bacterial infections, including acute pneumonias, sepsis, and chronic lung infections in patients with conditions like cystic fibrosis and chronic obstructive pulmonary disease, GLOX Therapeutics is positioned to make significant contributions to the field of antimicrobial therapy.

United Kingdom

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

GLOX Therapeutics Ltd.

Company Details